Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07650240CT.gov Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial | — | Not Yet Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07230106CT.gov A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer | — | Recruiting | — | — | — |
NCT07299292CT.gov Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | — | Recruiting | — | — | — |
NCT07198633CT.gov A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT05361915CT.gov Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | — | Suspended | — | — | — |
NCT06952803CT.gov A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | — | Recruiting | — | — | — |
NCT07406282CT.gov A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics | — | Recruiting | — | — | — |
NCT06991556CT.gov An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | — | Recruiting | — | — | — |
NCT06855277CT.gov Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | — | Recruiting | — | — | — |
Show 116 more trialsShow fewer
NCT07005154CT.gov A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | — | Recruiting | — | — | — |
NCT06527690CT.gov Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT06632977CT.gov Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | — | Recruiting | — | — | — |
NCT06768255CT.gov Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC | — | Not Yet Recruiting | — | — | — |
NCT06652607CT.gov PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06689163CT.gov A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | — | Recruiting | — | — | — |
NCT06384222CT.gov Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | — | Recruiting | — | — | — |
NCT06568094CT.gov A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT06505278CT.gov The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy | — | Not Yet Recruiting | — | — | — |
NCT06457919CT.gov A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | — | Recruiting | — | — | — |
NCT06378866CT.gov Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | — | Recruiting | — | — | — |
NCT05593497CT.gov A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss | — | Recruiting | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06212583CT.gov High-Risk Metachronous Oligometastatic Prostate Cancer Trial | — | Active Not Recruiting | — | — | — |
NCT05689021CT.gov CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | — | Active Not Recruiting | — | — | — |
NCT05574712CT.gov A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | — | Withdrawn | — | — | — |
NCT06134271CT.gov Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer | — | Unknown | — | — | — |
NCT06173362CT.gov Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT06099990CT.gov Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) | — | Not Yet Recruiting | — | — | — |
NCT03348670CT.gov Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms | — | Active Not Recruiting | — | — | — |
NCT06014853CT.gov A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | — | Completed | — | — | — |
NCT05733351CT.gov Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | — | Terminated | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05751941CT.gov Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05705700CT.gov Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | — | Withdrawn | — | — | — |
NCT05422911CT.gov Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | — | Recruiting | — | — | — |
NCT05288166CT.gov A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | — | Active Not Recruiting | — | — | — |
NCT05212857CT.gov Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT05167175CT.gov The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
NCT04812366CT.gov Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT04947254CT.gov Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04729114CT.gov A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04748042CT.gov Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | — | Active Not Recruiting | — | — | — |
NCT04734730CT.gov Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT05223582CT.gov Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial | — | Unknown | — | — | — |
NCT04736108CT.gov Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | — | Unknown | — | — | — |
NCT04677855CT.gov Study of PCUR-101 in Combination With ADT in Patients With mCRPC | — | Terminated | — | — | — |
NCT03902951CT.gov Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04194554CT.gov A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04296578CT.gov Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | — | Withdrawn | — | — | — |
NCT04493853CT.gov Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency | — | Active Not Recruiting | — | — | — |
NCT04421222CT.gov Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT04267887CT.gov Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03999515CT.gov Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | — | Terminated | — | — | — |
NCT03777982CT.gov Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04207255CT.gov Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | — | Completed | — | — | — |
NCT04221542CT.gov Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT05406999CT.gov Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04291664CT.gov PK and Dose Escalation and Expansion Study of DST-2970 | — | Terminated | — | — | — |
NCT04087174CT.gov A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT03821792CT.gov Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03860987CT.gov Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | — | Completed | — | — | — |
NCT02789878CT.gov Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | — | Completed | — | — | — |
NCT03706365CT.gov A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03678025CT.gov Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03511196CT.gov Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03298087CT.gov Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | — | Completed | — | — | — |
NCT03458247CT.gov Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer | — | Completed | — | — | — |
NCT03436654CT.gov Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT03360721CT.gov Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03418324CT.gov Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | — | Completed | — | — | — |
NCT03141671CT.gov Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | — | Unknown | — | — | — |
NCT03279250CT.gov Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | — | Completed | — | — | — |
NCT02867020CT.gov Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | — | Completed | — | — | — |
NCT03098836CT.gov Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03016741CT.gov Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02849990CT.gov A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | — | Completed | — | — | — |
NCT03009981CT.gov A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | — | Completed | — | — | — |
NCT02903160CT.gov Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
NCT02960022CT.gov A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | — | Recruiting | — | — | — |
NCT06473259CT.gov Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients | — | Recruiting | — | — | — |
NCT02903368CT.gov Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy | — | Completed | — | — | — |
NCT02807805CT.gov Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02887976CT.gov Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 | — | Completed | — | — | — |
NCT02543255CT.gov Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) | — | Completed | — | — | — |
NCT02772588CT.gov AASUR in High Risk Prostate Cancer | — | Completed | — | — | — |
NCT02737332CT.gov A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02758132CT.gov Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | — | Terminated | — | — | — |
NCT02353715CT.gov Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing | — | Completed | — | — | — |
NCT02366494CT.gov Micro RNAs to Predict Response to Androgen Deprivation Therapy | — | Completed | — | — | — |
NCT02268175CT.gov Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | — | Completed | — | — | — |
NCT02159690CT.gov A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | — | Withdrawn | — | — | — |
NCT02090114CT.gov RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | — | Completed | — | — | — |
NCT02218606CT.gov Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01994590CT.gov Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT02730975CT.gov Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02077634CT.gov Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE) | — | Completed | — | — | — |
NCT02097303CT.gov Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis | — | Completed | — | — | — |
NCT02049190CT.gov Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01995058CT.gov Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | — | Terminated | — | — | — |
NCT01949337CT.gov Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT01946165CT.gov Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | — | Completed | — | — | — |
NCT01995513CT.gov Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | — | Completed | — | — | — |
NCT01848067CT.gov Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01845792CT.gov Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT01828476CT.gov Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT01792687CT.gov Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | — | Completed | — | — | — |
NCT01751451CT.gov 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | — | Completed | — | — | — |
NCT01681433CT.gov OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | — | Terminated | — | — | — |
NCT01741753CT.gov BKM120+Abiraterone Acetate for Metastatic CRPC | — | Terminated | — | — | — |
NCT01685125CT.gov Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01685268CT.gov A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | — | Completed | — | — | — |
NCT01574937CT.gov XL-184+Abiraterone in Post-Chemo CRPC | — | Completed | — | — | — |
NCT01576172CT.gov Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01591122CT.gov Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01511536CT.gov Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01553188CT.gov AMG 386 and Abiraterone for Advanced Prostate Cancer | — | Completed | — | — | — |
NCT01485861CT.gov Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | — | Completed | — | — | — |
NCT01393730CT.gov Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01400555CT.gov A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Completed | — | — | — |
NCT01314118CT.gov IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | — | Completed | — | — | — |
NCT01254864CT.gov Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | — | Completed | — | — | — |
NCT01023061CT.gov Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abiraterone (this asset) | Mayo Clinic | Approved | BB · 67 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Abiraterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Carcinoma | — | P4 | BBB · 72 |
| Prostate Neoplasm | — | P3 | BB · 71 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abiraterone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abiraterone-prostate-cancer-77387
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →